{
    "clinical_study": {
        "@rank": "131159", 
        "acronym": "DDI", 
        "brief_summary": {
            "textblock": "To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the\n      pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when\n      administered with rifampin in healthy subjects"
        }, 
        "brief_title": "Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "-  In Treatment Period 1, subjects will receive a single 25 mg oral dose of IPI-145\n\n        -  In Treatment Period 2, on Days 3-9, the same subjects will receive once daily (QD) oral\n           doses of 600 mg rifampin; on Day 9, subjects will receive a single oral dose of 25 mg\n           IPI-145 concomitantly administered with 600 mg of rifampin"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy men or women of non-childbearing potential between 18-50 years of age\n\n          -  Body Mass Index (BMI): 18.0 - 32.0 kg/m2\n\n          -  In good health, determined by no clinically significant findings from clinical\n             evaluations\n\n          -  Provided written informed consent prior to any study specific procedures\n\n        Exclusion Criteria:\n\n          -  Women of childbearing potential\n\n          -  Evidence of clinically significant medical conditions\n\n          -  History of gastrointestinal disease or surgery that may affect drug absorption\n\n          -  Positive or indeterminate Tuberculosis -spot test at screening\n\n          -  Any active infection at the time of screening or admission\n\n          -  Consumption of any nutrients known to modulate cytochrome P450 enzyme activity within\n             14 days prior to administration of study drug, during the study, and until after\n             discharge"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01947777", 
            "org_study_id": "IPI-145-11"
        }, 
        "intervention": [
            {
                "description": "25 mg oral capsule", 
                "intervention_name": "IPI-145", 
                "intervention_type": "Drug"
            }, 
            {
                "description": "2x 300 mg oral capsule", 
                "intervention_name": "Rifampin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rifampin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Phase 1", 
            "Healthy subjects", 
            "DDI", 
            "CYP3A"
        ], 
        "lastchanged_date": "February 26, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lenexa", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66219"
                }, 
                "name": "PRA International, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of Rifampin (a CYP3A Inducer) on the Pharmacokinetics of IPI-145 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "PRA International, Inc", 
            "last_name": "Sandra Willsie", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetic parameters (AUC) of IPI-145 and its metabolite, IPI-656", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours"
            }, 
            {
                "measure": "Pharmacokinetic parameters (Cmax) of IPI-145 and its metabolite, IPI-656", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours"
            }, 
            {
                "measure": "Pharmacokinetic parameters (t1/2) of IPI-145 and its metabolite, IPI-656", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours"
            }, 
            {
                "measure": "Plasma concentrations of IPI-145 and its metabolite, IPI-656", 
                "safety_issue": "No", 
                "time_frame": "Over 48 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01947777"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Safety Findings", 
            "measure": "Incidence of adverse events following administration of IPI-145, rifampin, and the combination.", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "source": "Infinity Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Infinity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}